It is currently in phase 3 clinical trials (the TRIUMPH program) evaluating its safety and efficacy for chronic weight management
Researchers at tissue engineering labs consistently administer TB-500 based on lab schedule convenience, with zero correlation between injection timing and observed tissue regeneration markers (collagen deposition, neovascularization density, tensile strength recovery)
Medication was 10 g/kg BPC 157, 10 ng/kg BPC 157, or 5 mL/kg saline, given intraperitoneally, intragastrically, or as bath to the swollen brain above the sinus, at 15 min ligation-time, and recording (with a camera attached to a VMS-004 Discovery Deluxe USB microscope (Veho, Dayton, OH, USA)) performed through next 10 min time
All compounded formulations are prepared by Olympia Pharmaceuticals under cGMP guidelines and with oversight by national and state pharmacy boards